News
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
Gabapentin, which is used to treat seizures, nerve pain and restless leg syndrome might be linked with increased risk of ...
Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...
A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, ...
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims ...
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results